- EYEG -43% on announcing results for Phase 2b trial of EGP-437 in cataract surgery.
- More news on: EyeGate Pharmaceuticals, Corcept Therapeutics Incorporated, Digital Power Corporation, Stocks on the move, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.